It reactivated the Nrf2 pathway (36), most likely inhibited by ERS (44) and consequently reduced inflammatory response to CIS (49) and apoptosis, which is consistent with previous reports of ERS inhibition and anti-apoptotic (19, 50, 51) as well as the anti-inflammatory activity of CHA (52,53,54). The gene discussed is TCFL5; the disease is in situ carcinoma.